Balanced news tone
News Sentiment
IRON sentiment intelligence
Disc Medicine Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
51
Balanced news tone
54 relevant articles
News tone and price action are not far from neutral.
82/100 classification confidence.
directly relevant articles
high-authority source matches
-0.6% over one week, +7.6% over four weeks, trend inactive, and materially above fair value.
Going Deeper On Disc Medicine (NASDAQ:IRON)
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
82/100 classification
One-week reaction
-0.6%
Price digesting
Trend fit
Trend inactive
7.6% over four weeks
Fair value
31.0%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
12
Neutral
34
Negative
8
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Investing.com Canada
Direct company coverage
Form 4 Disc Medicine Inc For: 23 June By Investing.com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- Investing.com Canada
Stock Titan
Direct company coverage
Disc Medicine (NASDAQ: IRON) legal chief exercises options, sells 7,500 shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- Stock Titan
MT Newswires
Direct company coverage
Disc Medicine Insider Sold Shares Worth $1,287,801, According to a Recent SEC Filing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 20:48
- Source
- MT Newswires
Market source
Direct company coverage
Is Iron Mountain Stock Underperforming the Nasdaq?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- Market source
GlobeNewswire
Direct company coverage
Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 12 Jun 2026 12:30
- Source
- GlobeNewswire
GlobeNewswire
Direct company coverage
Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 12:30
- Source
- GlobeNewswire
GlobeNewswire
Direct company coverage
Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 02 Jun 2026 12:00
- Source
- GlobeNewswire
Simply Wall St.
Direct company coverage
How Investors May Respond To Disc Medicine (IRON) Expanding Pre-Approval Access To Bitopertin For Porphyria Patients
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 14:07
- Source
- Simply Wall St.
GlobeNewswire
Direct company coverage
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 12:30
- Source
- GlobeNewswire
MarketBeat
Direct company coverage
Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges
- Tone
- Positive 58/100
- Event
- Regulatory and legal
- Published
- 26 May 2026 04:04
- Source
- MarketBeat
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
MT Newswires
Direct company coverage
Morgan Stanley Raises Price Target on Disc Medicine to $80 From $75, Keeps Overweight Rating
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 14 May 2026 11:01
- Source
- MT Newswires
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
A Look At Disc Medicine (IRON) Valuation After Legal Probes And FDA Complete Response Letter
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 May 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
StocksToTrade
Direct company coverage
Disc Medicine’s Stock Dips as FDA Approves Pending Concerns
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Feb 2026 08:00
- Source
- StocksToTrade
timothysykes.com
Direct company coverage
Disc Medicine Faces Turmoil Amid FDA Concerns but Investors Not Losing Hope
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Feb 2026 08:00
- Source
- timothysykes.com
GlobeNewswire
Direct company coverage
Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jan 2025 08:00
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 25 Oct 2024 07:00
- Source
- Stock Titan
MarketBeat
Direct company coverage
Disc Medicine (IRON) Stock Price, News & Analysis $IRON
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jan 2023 22:33
- Source
- MarketBeat